Pfizer Inc. (NYSE:PFE) Shares Purchased by Hartford Financial Management Inc.

Hartford Financial Management Inc. raised its position in Pfizer Inc. (NYSE:PFEFree Report) by 8.8% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 6,529 shares of the biopharmaceutical company’s stock after purchasing an additional 529 shares during the quarter. Hartford Financial Management Inc.’s holdings in Pfizer were worth $173,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently made changes to their positions in PFE. Retirement Wealth Solutions LLC acquired a new stake in Pfizer in the 4th quarter valued at approximately $26,000. Gladius Capital Management LP lifted its holdings in Pfizer by 102.8% in the third quarter. Gladius Capital Management LP now owns 1,043 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 38,015 shares during the period. Quarry LP bought a new position in Pfizer in the 2nd quarter valued at about $31,000. Teachers Insurance & Annuity Association of America acquired a new position in Pfizer during the 3rd quarter valued at about $35,000. Finally, Joseph Group Capital Management raised its position in shares of Pfizer by 168.3% during the 3rd quarter. Joseph Group Capital Management now owns 1,229 shares of the biopharmaceutical company’s stock worth $36,000 after buying an additional 771 shares in the last quarter. Institutional investors own 68.36% of the company’s stock.

Analyst Ratings Changes

PFE has been the topic of several recent research reports. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $45.00 price objective on shares of Pfizer in a research note on Wednesday, October 23rd. Guggenheim reduced their target price on Pfizer from $35.00 to $33.00 and set a “buy” rating for the company in a report on Wednesday, December 11th. Evercore ISI upgraded Pfizer to a “strong-buy” rating in a report on Wednesday, October 30th. Wolfe Research began coverage on shares of Pfizer in a report on Friday, November 15th. They issued an “underperform” rating and a $25.00 target price for the company. Finally, Truist Financial cut their price target on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a report on Wednesday, December 18th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have assigned a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $31.92.

Read Our Latest Analysis on Pfizer

Pfizer Stock Performance

PFE stock opened at $26.89 on Friday. The firm has a 50 day moving average of $26.22 and a two-hundred day moving average of $27.90. Pfizer Inc. has a 12 month low of $24.48 and a 12 month high of $31.54. The company has a market capitalization of $152.41 billion, a price-to-earnings ratio of 36.34, a P/E/G ratio of 0.64 and a beta of 0.64. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63.

Pfizer (NYSE:PFEGet Free Report) last posted its earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 EPS for the quarter, topping the consensus estimate of $0.64 by $0.42. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. The firm had revenue of $17.70 billion for the quarter, compared to the consensus estimate of $14.92 billion. During the same period in the prior year, the business posted ($0.17) earnings per share. The business’s quarterly revenue was up 31.2% on a year-over-year basis. As a group, equities analysts anticipate that Pfizer Inc. will post 2.96 EPS for the current fiscal year.

Pfizer Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, January 24th will be issued a dividend of $0.43 per share. This is a positive change from Pfizer’s previous quarterly dividend of $0.42. The ex-dividend date of this dividend is Friday, January 24th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.40%. Pfizer’s dividend payout ratio is currently 232.44%.

About Pfizer

(Free Report)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Further Reading

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFEFree Report).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.